195 related articles for article (PubMed ID: 16676687)
1. A clinical and immunohistochemical study of gastrointestinal stromal tumours.
Khoo JJ; Gunn A
Malays J Pathol; 2005 Jun; 27(1):9-16. PubMed ID: 16676687
[TBL] [Abstract][Full Text] [Related]
2. Revision of gastrointestinal mesenchymal tumours with CD117.
de Schipper JP; Liem RS; van den Ingh HF; van der Harst E
Eur J Surg Oncol; 2004 Nov; 30(9):959-62. PubMed ID: 15498641
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features, cellular differentiation, PCNA and P53 expressions in gastrointestinal stromal tumors.
Can B; Sökmensüer C
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxliii-ccxlviii. PubMed ID: 15244191
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico.
Alvarado-Cabrero I; Vázquez G; Sierra Santiesteban FI; Hernández-Hernández DM; Pompa AZ
Ann Diagn Pathol; 2007 Feb; 11(1):39-45. PubMed ID: 17240306
[TBL] [Abstract][Full Text] [Related]
5. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome.
Reith JD; Goldblum JR; Lyles RH; Weiss SW
Mod Pathol; 2000 May; 13(5):577-85. PubMed ID: 10824931
[TBL] [Abstract][Full Text] [Related]
6. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
[TBL] [Abstract][Full Text] [Related]
7. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies.
Hassan I; You YN; Dozois EJ; Shayyan R; Smyrk TC; Okuno SH; Donohue JH
Dis Colon Rectum; 2006 May; 49(5):609-15. PubMed ID: 16552495
[TBL] [Abstract][Full Text] [Related]
8. [Expression of CD117, CD34, SMA, S-100 protein, Vim and desmin in patients with gastrointestinal stromal tumors].
Liu J; Liu YH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):438-40. PubMed ID: 18359707
[TBL] [Abstract][Full Text] [Related]
9. Prognostic analysis of rectal stromal tumors by reference of National Institutes of Health risk categories and immunohistochemical studies.
Tsai MC; Lin JW; Lin SE; Chen HH; Lee CM; Hu TH
Dis Colon Rectum; 2008 Oct; 51(10):1535-43. PubMed ID: 18633679
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
11. "Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction.
Abraham SC; Krasinskas AM; Hofstetter WL; Swisher SG; Wu TT
Am J Surg Pathol; 2007 Nov; 31(11):1629-35. PubMed ID: 18059218
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic spectrum of gastro intestinal stromal tumours - experience at a tertiary care center.
Ravikumar G; Kalegowda IY; Ananthamurthy A
Indian J Cancer; 2011; 48(4):466-70. PubMed ID: 22293262
[TBL] [Abstract][Full Text] [Related]
13. Gastro-intestinal stromal tumour--role of CD117 in diagnosis and management.
Paul PC; Chakraborty J; Kundu D; Sarkar R
Indian J Pathol Microbiol; 2007 Apr; 50(2):279-83. PubMed ID: 17883045
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
15. High incidence of microscopic gastrointestinal stromal tumors in the stomach.
Kawanowa K; Sakuma Y; Sakurai S; Hishima T; Iwasaki Y; Saito K; Hosoya Y; Nakajima T; Funata N
Hum Pathol; 2006 Dec; 37(12):1527-35. PubMed ID: 16996566
[TBL] [Abstract][Full Text] [Related]
16. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours.
Ryu MH; Kang YK; Jang SJ; Kim TW; Lee H; Kim JS; Park YH; Lee SS; Ryoo BY; Chang HM; Lee JL; Yook JH; Kim BS; Lee JS
Histopathology; 2007 Sep; 51(3):379-89. PubMed ID: 17727479
[TBL] [Abstract][Full Text] [Related]
18. Histopathological and immunohistochemical features of gastrointestinal stromal tumors.
Fülöp E; Marcu S; Borda A; Moldovan C; Fülöp EF; Loghin A; Pávai Z
Rom J Morphol Embryol; 2011; 52(2):555-62. PubMed ID: 21655642
[TBL] [Abstract][Full Text] [Related]
19. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
20. Predictors of malignant behaviour in gastrointestinal stromal tumours: a clinicopathological study of 34 cases.
Abdulkader I; Cameselle-Teijeiro J; Gude F; Fraga M; Varela-Durán J; Barreiro F; Forteza J
Eur J Surg; 2002; 168(5):288-96. PubMed ID: 12375611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
